Abbott Laboratories (ABT) DIvidends Date & History

Key Takeaways

• Abbott Laboratories (ABT) offers a forward dividend yield of 2.82%, providing reliable income for investors.
• The company has raised its dividend for 52 consecutive years, earning Dividend King status with 399+ quarterly payments since 1924.
• Quarterly dividend stands at $0.63 per share, annualized to $2.52, with the latest ex-dividend date on April 15, 2026.
• Payout ratio of 67.23% is manageable, supported by strong free cash flow of $6.35 billion in 2024 and low debt-to-equity ratio of 0.19.
• ABT's yield exceeds the medical devices industry average of about 1.5%, appealing to income-focused investors.

Dividend Overview

Abbott Laboratories (ABT), a diversified healthcare company specializing in medical devices, diagnostics, and nutritionals, maintains a robust dividend policy. The current quarterly dividend is $0.63 per share, equating to an annualized forward dividend of $2.52 and a forward yield of 2.82%. Payments occur quarterly, with the most recent ex-dividend date on April 15, 2026, and payment on May 15, 2026. ABT qualifies as a dividend growth stock, having consistently raised payouts for over five decades, balancing income reliability with moderate yield in the healthcare sector. This profile attracts investors seeking steady returns amid the company's innovation in products like FreeStyle Libre glucose monitoring.

Dividend History and Growth

Abbott Laboratories has a storied dividend history, declaring 399 consecutive quarterly dividends since 1924 and increasing the annual payout for 52 straight years as of 2026. The latest hike to $0.63 quarterly from $0.59 represents a 6.8% increase, continuing a trend of mid-single-digit annual growth. Since the 2013 spin-off of AbbVie, dividends have more than doubled, reflecting disciplined capital allocation and earnings growth. This consistency underscores ABT's long-term strategy of rewarding shareholders through reliable, growing distributions without cuts in its century-plus history.

Dividend Sustainability and Payout Ratio

ABT's dividend appears highly sustainable, with a payout ratio of 67.23% of earnings, leaving room for reinvestment and growth. Free cash flow (FCF) of $6.35 billion in 2024 comfortably covers the approximately $4.4 billion annual dividend obligation, yielding an FCF payout ratio around 60-70%. A low debt-to-equity ratio of 0.19 signals financial stability, minimizing risks to payouts. Earnings coverage remains solid, supported by diversified revenue streams, positioning the dividend for continued growth.

Dividend Compared to Industry Peers

ABT's 2.82% forward yield stands out in the medical devices sector, surpassing the industry average of roughly 1.5%. Peers like Stryker (SYK) yield about 1.0%, while Boston Scientific (BSX) pays no dividend, prioritizing growth. Medtronic (MDT) offers a higher 3.5%, but ABT's superior growth streak and lower payout ratio provide a balanced profile. Compared to Johnson & Johnson (JNJ) at around 3%, ABT delivers competitive income with strong sustainability in healthcare equipment.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. It efficiently identifies dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities. Explore the AI Screener to enhance your screening process today.

Is This Stock Attractive for Dividend Investors?

Abbott Laboratories (ABT) appeals to dividend growth investors valuing long-term consistency, given its 52-year increase streak and moderate 2.82% yield backed by robust FCF coverage. Income-oriented portfolios may find its quarterly payouts reliable, especially amid healthcare sector stability. Conservative investors appreciate the low debt levels and S&P 500 Dividend Aristocrat status, offering defense against volatility. However, those seeking ultra-high yields above 4% might look elsewhere, as ABT prioritizes balanced growth over maximum current income. Long-term holders benefit from the company's innovation pipeline, but sector risks like regulatory changes warrant monitoring. Overall, ABT suits patient investors focused on compounding returns through sustainable dividend hikes.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations